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Abstract
The emergence of Klebsiella pneumoniae producing carbapenemase (KPC) has now become a global concern. As a part of a nationwide
multicentre surveillance study in Cuba, three K. pneumoniae clinical isolates resistant to carbapenems were detected for a 1-month period
(September to October 2011). PCR and sequence analysis revealed that the three strains harboured blaKPC-2. They showed resistance or
intermediate susceptibility to expanded-spectrum cephalosporins, other b-lactams, a b-lactam/b-lactamase inhibitor combination, and
gentamicin. Two strains were susceptible only to colistin, whereas the other strain showing colistin resistance was susceptible to
ﬂuoroquinolones. These blaKPC-2-positive K. pneumoniae strains were classiﬁed into ST1271 (CC29), a novel clone harbouring blaKPC-2, and
were revealed to be genetically identical by PCR-basedDNAﬁngerprinting. The three patients infectedwith the KPC-producing K. pneumoniae
had common risk factors, and had no overseas travel experience outside Cuba, suggesting local acquisition of the resistant pathogen. This is the
ﬁrst report of a KPC-producing K. pneumoniae in Cuba. Although detection of KPC in Enterobacteriaceae is still rare in Cuba, our ﬁnding
indicated that KPC-producing bacteria are a global concern and highlighted the need to identify these microorganisms in clinical laboratories.
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Introduction
The Klebsiella pneumoniae carbapenemase (KPC) was ﬁrst
described in 1996 in North Carolina, USA. Thereafter,
expansion of KPC in clinical isolates has been reported from
different continents associated with the global spread of the
clonal lineages of K. pneumoniae, such as ST248/ST258 [1]. The
ST258 K. pneumoniae has been described as an international
KPC-producing clone [2], and its global spread including Latin
American countries has also been reported [3]. Because the
KPC gene is carried by plasmids, potentially rapid transmission
of carbapenem resistance has been recognized as a major
threat to the antimicrobial treatment of infections with
gram-negative microorganisms [2]. The Pan American Health
Organization issued an epidemiological alert with the increase
of carbapenemase in Enterobacteriaceae from many Latin
American countries in 2010 [4]. Since then, Cuba has initiated
a surveillance network for K. pneumoniae clinical isolates from
reference hospitals to analyse their antimicrobial susceptibility
and genetic mechanisms of drug resistance with special
attention to carbapenem resistance, in the ‘Pedro Kourı’
Institute of Tropical Medicine [5]. During this national
surveillance, three isolates of KPC-producing K. pneumoniae
were detected for the ﬁrst time in Cuba.
Methods
As a part of a nationwide multicentre surveillance study in
Cuba, three K. pneumoniae clinical isolates resistant to carba-
penems were detected in the ‘Pedro Kourı’ Institute of
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Tropical Medicine for a 1-month period (September to
October 2011). The antimicrobial susceptibility to a wide
range of antibiotics was determined using E-test (BioMerieux,
Marcy l’Etoile, France) according to the manufacturer’s
recommendation. MICs were interpreted into susceptible or
resistant according to CLSI guidelines, 2012 [6], except for
colistin, which was judged by EUCAST criteria (susceptible
≤2 g/mL, resistant ≥4 g/mL), (http://www.eucast.org/clinical
breakpoints/). A double-disc synergy test was performed to
detect extended spectrum b-lactamases (ESBLs) [6] and 3-
aminophenylboronic acid test was used to screen for produc-
tion of carbapenemases [7]. The presence of genes encoding
carbapenemase was determined by PCR using protocols and
conditions as described previously [8]. Nucleotide sequence of
blaKPC was determined by direct sequencing with PCR
products by using the BigDye Terminator version 3.1 cycle
sequencing kit (Applied Biosystems, Foster City, CA, USA).
Sequence type (ST) of K. pneumoniae based on the scheme of
multilocus sequence typing (MLST) was determined according
to the methods available at the website (www.pasteur.fr/
recherche/genopole/PF8/mlst/Kpneumoniae.html). KPC-2
gene sequence of K. pneumoniae strain 354 was deposited to
GenBank database under accession no. KJ151293. To analyse
genetic diversity of K. pneumoniae isolates, genomic DNA
ﬁngerprinting was performed by randomly ampliﬁed polymor-
phic DNA analysis with the use of a single primer (M13, ERIC-
2, AP-1, AP-4 and AP-7), and repetitive extragenic palindromic
sequence-based PCR (REP-PCR) with a pair of primers
(REP1R-I, REP2-I), as described previously [9–13].
Results and Discussion
Three clinical isolates of K. pneumoniae (strains 328, 354, 355)
recovered from two provinces of Cuba (Holguin and Havana
city) were conﬁrmed to be resistant to imipenem and
meropenem. These strains showed resistance or intermediate
susceptibility to expanded-spectrum cephalosporins, b-lactam,
b-lactam/b-lactamase inhibitor combination (piperacillin/tazo-
bactam), and gentamicin. Two of these strains (354, 355) were
susceptible only to colistin, whereas the other strain (328)
showing resistance to colistin was susceptible to ﬂuoroqui-
nolones (Table 1). The synergy test to detect ESBLs and
carbapenemase was positive, suggesting the production of an
ESBL and KPC enzyme. The KPC gene was detected in the
three strains by PCR, and their sequences were revealed to be
identical to blaKPC-2. The three blaKPC-2-positive K. pneumoniae
strains were classiﬁed into ST1271 (CC29), a single locus
variant of ST29. The ST1271 was identiﬁed as a novel clone
harbouring blaKPC-2 in the present study, because the presence
of blaKPC-2 had not been reported in ST1271 as well as ST29
clones. By randomly ampliﬁed polymorphic DNA analysis with
ﬁve different primers and REP PCR, three strains showed the
same banding patterns (Fig. 1), indicating that these strains are
genetically identical and have the same origin. The two
colistin-susceptible strains were derived from the same
hospital in Havana, exhibited similar resistance patterns, and
are suggested to be the same strain that had transmitted via
nosocomial infection.
The three strains with KPC genes were derived from two
separate provinces, i.e. Holguin (eastern Cuba) and Havana city
(western Cuba). Patients infected with the KPC-producing
K. pneumoniae had no experience of travel outside Cuba,
suggesting that local acquisition and a silent dissemination of
the KPC-positive K. pneumoniae ST1271 clone in this country.
Because intercontinental travel has been directly linked with
the spread of KPCs through patients colonized or infected
with KPC-producing K. pneumoniae [14,15], international
tourism might have played an important role in its emergence
in Cuba. ST29 K. pneumoniae strains have been isolated from
Europe, e.g. Spain and Greece, and also from Brazil [3]. In our
previous report on the antimicrobial resistance of K. pneumo-
niae in Cuba through the national surveillance programme
(2009–10), 54 isolates (23.6%) were positive for ESBL, and
were classiﬁed into 27 STs, showing high clonal diversity [5].
However, none of the ST identiﬁed in the ESBL-positive
isolates belonged to CC29. Therefore, in Cuba, the ST1271
K. pneumoniae strains are genetically distinct from ESBL-posi-
tive strains. Although the origin of the ST1271 strains has yet
to be determined, it is possible that ST1271 might have been
brought from another country recently, associated with
acquisition of the KPC gene. Further molecular epidemiolog-
TABLE 1. Antimicrobial susceptibility of Klebsiella pneumo-
niae clinical isolates producing KPC-2 carbapenemase
Antibiotics
MIC Interpretationa
Strain 328 Strain 354 Strain 355
Piperacillin/tazobactam R R R
Cefotaxime R R R
Ceftazidime R R R
Cefoxitin S R R
Cefepime R R R
Aztreonam R R R
Meropenem R R R
Imipenem R R I
Amikacin R R I
Gentamicin R R R
Colistin R S S
Ciproﬂoxacin S R R
Levoﬂoxacin S R R
Nalidixic acid S R R
Trimethoprim-
sulfamethoxazole
R R R
R, Resistant; S, susceptible; I, Intermediate.
aAccording to CLSI standards (2012).
ª 2014 The Authors. New Microbes and New Infections published by John Wiley & Sons Ltd on behalf of the European Society of Clinical Microbiology and Infectious Disease., NMNI, 2, 123–126
124 New Microbes and New Infections, Volume 2 Number 4, July 2014 NMNI
Open access under CC BY license.
ical studies on K. pneumoniae isolates, including those from
healthy individuals, may provide more information on distri-
bution and transmission of the ST1271 clone.
It was noted in the present study that an ST1271
K. pneumoniae strain showed resistance to colistin. Generally,
the colistin resistance rate of K. pneumoniae has been reported
to be low [16]. During the period of antimicrobial resistance
surveillance (2010–12) of Klebsiella spp. in Cuba, we notiﬁed
15% colistin resistance, which would be of great concern in
clinical settings [17]. Our present ﬁnding indicates that the
colistin resistance has emerged in multidrug-resistant K. pneu-
moniae. This antibiotic is recognized as a key therapeutic
option for carbapenem-resistant bacteria, and is particularly
important in countries with limited resources, such as Cuba
where tigecycline is not available.
Table 2 shows the clinical information of three patients
infected with K. pneumoniae producing KPC-2 carbapenemase.
These patients had common risk factors, such as prolonged
hospitalization, intravenous catheter, previous antimicrobial
therapy, and underlying disease. These ﬁndings are consistent
with previous studies that notiﬁed risk factors for acquiring
infections with KPC-producing K. pneumoniae [18]. In the
present study, all three K. pneumoniae producing KPC were
isolated from blood specimens and two of the patients died
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FIG. 1. DNA ﬁngerprints obtained by randomly ampliﬁed polymorphic DNA analysis with primer M13 (lanes 1–3), ERIC2 (lanes 4–6), AP-1 (lanes
7–9), AP-4 (lanes 10–12), and AP-7 (lanes 13–15), and repetitive extragenic palindromic sequence-based PCR (lanes 16–18). Lanes 1, 4, 7, 10, 13, 16,
strain 328; lanes 2, 5, 8, 11, 14, 17, strain 354; lanes 3, 6, 9, 12, 15, 18, strain 355. Lane ‘M’ represents DNA size marker and molecular size (bp) is
shown on the left.
TABLE 2. Clinical information of patients infected with Klebsiella pneumoniae producing KPC-2 carbapenemase
Cases Age Sex Province Hospital Department
Isolation
date Risk factors Disease Specimen Final therapy Died
Case-1
(strain
328)
42 Male Holguın
(Eastern
Cuba)
1 Intensive care
unit
September
2011
Previous antimicrobial
therapy, urinary
catheter, prolonged
hospitalization,
intravenous catheter
Underlying disease
(Haemorrhage
itraparenkimatosa)
Septicaemia Blood Ciproﬂoxacin No
Case-2
(strain
354)
49 Female Havana city
(Western
Cuba)
2 Marrow
transplant
unit
October
2011
Previous antimicrobial
therapy, chemotherapy
gynaecological surgery
prolonged hospitalization,
intravenous catheter
Underlying disease
(Acute myeloid
leukaemia)
Cellulitis in
surgery site
Septic shock
Blood Cefepime, amikacin,
vancomycin and
amphotericin B
Yes
Case-3
(strain
355)
57 Female Havana city
(Western
Cuba)
2 Intensive care
unit
October
2011
Previous antimicrobial
therapy, surgery for
valve replacement,
mechanical ventilation
urinary catheter,
prolonged hospitalization,
intravenous catheter,
Underlying disease
(Mitral stenosis)
Pneumonia
Paralytic ileus
Cardiogenic
shock
Septic shock
Blood Colistin plus
amphotericin B
Yes
KPC, Klebsiella pneumoniae producing carbapenemase.
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with septic shock. The susceptibility proﬁle of these isolates
indicated considerably limited therapeutic options, i.e. colistin
in two patients or ﬂuoroquinolone in one patient. The optimal
treatment for infections caused by KPC-producing K. pneumo-
niae has been difﬁcult to describe, resulting in mortality rates
of at least 50% [19]. Therefore, evaluation of effective
antibiotic options and rigorous infection control measures
may be necessary to reduce carbapenemase-producing micro-
organisms.
Detection of the novel KPC-producing K. pneumoniae clone
(ST1271) in the present study demonstrated the importance of
monitoring hospitalized patients for the further emergence of
carbapenem resistance in K. pneumoniae as well as in other
gram-negative pathogens. Although carbapenemase-producing
Enterobacteriaceae are still rare in Cuba, our ﬁnding con-
ﬁrmed that KPC-producing isolates are a global concern,
highlighting the need to identify these microorganisms in
clinical laboratories.
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